Amendment 1. Changes requested by German regulatory authority BfArM: -Further rationale for patient selection was added to the protocol to justify the inclusion of participants with ACT score ≤19 (5-19). -The use of other asthma mediation was clarified. -Time period for the use of the controller medication at constant dose from at least 1 month was extended to 3 months prior to the screening visit. -A summary of pertinent safety information was included. -The 6-week phone call was removed in order not to create bias. -Pregnancy testing was included to screening for WOCBP -The requirement for WOCBP to use adequate contraception was included. -Paradoxical bronchospasm was added as an example for discontinuing the trial treatment for a participant. -Criteria for discontinuation of the trial were added. -The use of Salbutamol Easyhaler as a reliever medication was clarified. -A new section containing potent inhibitors of CYP3A was added. -Trial procedures at screening were clarified. -It was clarified that participants can call Propeller customer support if they have any questions or concerns related to the sensor or the application. -More detailed information on spirometric measurements was given. -Clarification for pregnancy during the trial was added. -Text concerning discontinuation of the trial was reorganised and added under section 4.7. -Detailed information on contraception methods considered acceptable in this trial based on the Clinical Trial Facilitation Group recommendation was added.

The amended protocol was created to implement changes requested by German central ethics committee. -Primary objective was clarified. - Secondary objectives were clarified. -Timeline the participant had used an investigational drug was determined more precisely. -Exclusion of individuals who are subordinate to the Sponsor or institutionalised as a result of an administrative or court order were added. -Race as a data to be collected was removed. -Protocol deviation as a reason for participant’s discontinuation was removed -A reason for discontinuing the trial was added. -Ratio for distribution into treatment groups were added. -Easyhaler inhaler technique checking and training missing from randomisation visit was added. -Data related to variable Healthcare utilisation related to asthma to be collected from CRF was removed. -Data related to variable Number of missing working or trial days due to asthma symptoms to be collected from CRF was removed. -Clarification that non-compliance is not considered as a protocol deviation for per-protocol population was added. -Statistical analysis for the primary endpoint was described in more detail. -Clarification related to secondary variable adherence to controller medication was added.

An amendment to a protocol was created and implemented due to Covid-19 pandemic. -Obtaining baseline data about adherence was added. -Benefit-risk assessment was updated to include the possible risks associated with Covid-19. -The smart phone versions supported were updated. -Time from previous upper or lower respiratory infection was prolonged from 7 to 14 days due to possible covid-19 infection. -The need to return Easyhaler inhalers at every visit was removed because post-randomisation visits (Visit 3 and Visit 4) could have been carried out remotely (a telephone visit, home visit or video call) due to restrictions related to covid-19. -Asthma symptom control was removed as it was accidentally included into the original protocol. Assessment of asthma control according to GINA was considered at the time of protocol development but left out as ACT was included. This correction was missed in the previous amendments. -The precautions due to Covid-19 pandemic and possible protocol assessments during remote visits were added. -Clarifications into data collection was added.

An amendment was created to implement the changes requested by German central ethics committee. -Additional covid-19 precautions including covid-19 testing were added. -Trial dates (start and complete) were updated due to Covid-19.